Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study

Authors: Karlien François, Karl Martin Wissing, Rita Jacobs, Dries Boone, Kristine Jacobs, Christian Tielemans

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Since October 2010, the combination of a heparin-grafted polyacrilonitrile (AN69ST) membrane with a 0.80 mmol/L citric acid-containing dialysate is routinely used in our centre for intermittent haemodialysis, without systemic anticoagulation, in critically ill patients with increased bleeding risk. The primary outcome of this retrospective cohort study was to assess the development of circuit clotting during these dialysis procedures. Secondly, we assessed the impact of clotting on treatment duration, the incidence rate of coagulation-induced retransfusion failure and the association of patient and dialysis characteristics with the occurrence of clotting.

Methods

Dialysis and patient data on consecutive intermittent haemodialysis procedures, performed at the Intensive Care Unit of Universitair Ziekenhuis Brussel between October 2010 and March 2012, were retrospectively reviewed. We used descriptive statistics as well as a random effects logit model with patient identity as a panel variable to assess associations.

Results

Of a total of 309 treatments combining a heparin-grafted AN69ST membrane and a 0.8 mmol/L citric acid-enriched dialysate in 94 patients, circuit clotting was reported in 17.5% (95% CI 13.2% to 21.7%; N = 54), and in 19% (95% CI 13.6% to 24.4%; N = 40) of sessions with prescribed treatment time ≥ 4 hours (N = 210). Clotting shortened treatment time in 15.2% (95% CI 11.4% to 19.7%; N = 47) of sessions by a median of 55 (IQR 20 to 80) minutes. Complete clotting of the circuit with inability for retransfusion occurred in 4.2% (95% CI 2.2% to 7.0%; N = 13) of sessions. Circuit coagulation was not associated with APACHE II score, patient age, gender, number of treatments, type of vascular access or ultrafiltration rate.

Conclusion

Intermittent haemodialysis without systemic anticoagulation combining a heparin-grafted AN69ST dialyzer with a citrate-enriched dialysate favourably compares as to clotting complications with the published outcomes of anticoagulation-free intermittent haemodialysis strategies using saline flushes, heparin-coated dialyzer in combination with regular dialysate or regional citrate anticoagulation with calcium supplemented dialysate. The incidence of circuit clotting in our cohort appears to be higher than previously reported for regional citrate anticoagulation with a calcium-free dialysate.
Literature
1.
go back to reference European Best Practice Guidelines Expert Group on Hemodialysis ERA: Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002, 17 (Suppl 7): 63-71. European Best Practice Guidelines Expert Group on Hemodialysis ERA: Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002, 17 (Suppl 7): 63-71.
2.
go back to reference Casati S, Moia M, Graziani G, Cantaluppi A, Citterio A, Mannucci PM, Ponticelli C: Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol. 1984, 21 (2): 102-105.PubMed Casati S, Moia M, Graziani G, Cantaluppi A, Citterio A, Mannucci PM, Ponticelli C: Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol. 1984, 21 (2): 102-105.PubMed
3.
go back to reference Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis. 1985, 5 (1): 32-35. 10.1016/S0272-6386(85)80132-3.CrossRefPubMed Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis. 1985, 5 (1): 32-35. 10.1016/S0272-6386(85)80132-3.CrossRefPubMed
4.
go back to reference Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: comparative data and results in high risk patients. Kidney Int. 1987, 31 (6): 1351-1355. 10.1038/ki.1987.149.CrossRefPubMed Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: comparative data and results in high risk patients. Kidney Int. 1987, 31 (6): 1351-1355. 10.1038/ki.1987.149.CrossRefPubMed
5.
go back to reference Schwab SJ, Onorato JJ, Sharar LR, Dennis PA: Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med. 1987, 83 (3): 405-410. 10.1016/0002-9343(87)90748-0.CrossRefPubMed Schwab SJ, Onorato JJ, Sharar LR, Dennis PA: Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med. 1987, 83 (3): 405-410. 10.1016/0002-9343(87)90748-0.CrossRefPubMed
6.
go back to reference Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP: Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol. 2004, 62 (1): 29-34.CrossRefPubMed Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP: Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol. 2004, 62 (1): 29-34.CrossRefPubMed
7.
go back to reference Maurice L, Marc D, Joan F, Renaud F, Frederique M, Nathalie L, Patrick R: A randomized controlled multicenter trial of a heparin-grafted polyacrylonitrile membrane for no-heparin hemodialysis versus standard-of-care: results of the HepZero Study. Late-breaking clinical trial posters ISN World Congress of Nephrology 2013 SA-PO1084. Clin J Am Soc Nephrol. 2013, 24: 4B- Maurice L, Marc D, Joan F, Renaud F, Frederique M, Nathalie L, Patrick R: A randomized controlled multicenter trial of a heparin-grafted polyacrylonitrile membrane for no-heparin hemodialysis versus standard-of-care: results of the HepZero Study. Late-breaking clinical trial posters ISN World Congress of Nephrology 2013 SA-PO1084. Clin J Am Soc Nephrol. 2013, 24: 4B-
8.
go back to reference Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer HH, Morgera S: Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol. 2007, 68 (5): 302-307.CrossRefPubMed Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer HH, Morgera S: Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol. 2007, 68 (5): 302-307.CrossRefPubMed
9.
go back to reference Kreuzer M, Bonzel KE, Buscher R, Offner G, Ehrich JH, Pape L: Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol Dial Transplant. 2010, 25 (10): 3337-3342. 10.1093/ndt/gfq225.CrossRefPubMed Kreuzer M, Bonzel KE, Buscher R, Offner G, Ehrich JH, Pape L: Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol Dial Transplant. 2010, 25 (10): 3337-3342. 10.1093/ndt/gfq225.CrossRefPubMed
10.
go back to reference Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis. 2005, 45 (3): 557-564. 10.1053/j.ajkd.2004.12.002.CrossRefPubMed Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis. 2005, 45 (3): 557-564. 10.1053/j.ajkd.2004.12.002.CrossRefPubMed
11.
go back to reference Gubensek J, Kovac J, Benedik M, Marn-Pernat A, Knap B, Ponikvar R, Buturovic-Ponikvar J: Long-term citrate anticoagulation in chronic hemodialysis patients. Ther Apher Dial. 2011, 15 (3): 278-282. 10.1111/j.1744-9987.2011.00951.x.CrossRefPubMed Gubensek J, Kovac J, Benedik M, Marn-Pernat A, Knap B, Ponikvar R, Buturovic-Ponikvar J: Long-term citrate anticoagulation in chronic hemodialysis patients. Ther Apher Dial. 2011, 15 (3): 278-282. 10.1111/j.1744-9987.2011.00951.x.CrossRefPubMed
12.
go back to reference Ahmad S, Callan R, Cole JJ, Blagg CR: Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis. 2000, 35 (3): 493-499. 10.1016/S0272-6386(00)70203-4.CrossRefPubMed Ahmad S, Callan R, Cole JJ, Blagg CR: Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis. 2000, 35 (3): 493-499. 10.1016/S0272-6386(00)70203-4.CrossRefPubMed
13.
go back to reference Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009, 4 (9): 1459-1464. 10.2215/CJN.02590409.CrossRefPubMedPubMedCentral Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009, 4 (9): 1459-1464. 10.2215/CJN.02590409.CrossRefPubMedPubMedCentral
14.
go back to reference Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P: The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant. 2008, 23 (6): 2003-2009. 10.1093/ndt/gfm888.CrossRefPubMed Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P: The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant. 2008, 23 (6): 2003-2009. 10.1093/ndt/gfm888.CrossRefPubMed
15.
go back to reference Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA: Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012, 33 (1–3): 199-204.CrossRefPubMed Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA: Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012, 33 (1–3): 199-204.CrossRefPubMed
16.
go back to reference Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y: Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007, 49 (5): 642-649. 10.1053/j.ajkd.2007.02.001.CrossRefPubMed Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y: Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007, 49 (5): 642-649. 10.1053/j.ajkd.2007.02.001.CrossRefPubMed
17.
go back to reference Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005, 294 (7): 813-818. 10.1001/jama.294.7.813.CrossRefPubMed Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005, 294 (7): 813-818. 10.1001/jama.294.7.813.CrossRefPubMed
18.
go back to reference Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006, 10 (3): R73-10.1186/cc4915.CrossRefPubMedPubMedCentral Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006, 10 (3): R73-10.1186/cc4915.CrossRefPubMedPubMedCentral
19.
go back to reference Goldberg R, Dennen P: Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis. 2008, 15 (3): 297-307. 10.1053/j.ackd.2008.04.009.CrossRefPubMed Goldberg R, Dennen P: Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis. 2008, 15 (3): 297-307. 10.1053/j.ackd.2008.04.009.CrossRefPubMed
20.
go back to reference Lines SW, Cherukuri A, Murdoch SD, Bellamy MC, Lewington AJ: The outcomes of critically ill patients with acute kidney injury receiving renal replacement therapy. Int J Artif Organs. 2011, 34 (1): 2-9. 10.5301/IJAO.2011.6312.CrossRefPubMed Lines SW, Cherukuri A, Murdoch SD, Bellamy MC, Lewington AJ: The outcomes of critically ill patients with acute kidney injury receiving renal replacement therapy. Int J Artif Organs. 2011, 34 (1): 2-9. 10.5301/IJAO.2011.6312.CrossRefPubMed
21.
go back to reference Lazarus JM: Complications in hemodialysis: an overview. Kidney Int. 1980, 18 (6): 783-796. 10.1038/ki.1980.197.CrossRef Lazarus JM: Complications in hemodialysis: an overview. Kidney Int. 1980, 18 (6): 783-796. 10.1038/ki.1980.197.CrossRef
22.
go back to reference Janssen MJ, van der Meulen J: The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med. 1996, 48 (5): 198-207. 10.1016/0300-2977(96)00005-8.CrossRefPubMed Janssen MJ, van der Meulen J: The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med. 1996, 48 (5): 198-207. 10.1016/0300-2977(96)00005-8.CrossRefPubMed
23.
go back to reference Franchini M, Veneri D, Lippi G: Inflammation and hemostasis: a bidirectional interaction. Clin Lab. 2007, 53 (1–2): 63-67.PubMed Franchini M, Veneri D, Lippi G: Inflammation and hemostasis: a bidirectional interaction. Clin Lab. 2007, 53 (1–2): 63-67.PubMed
24.
go back to reference Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M: Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J. 2005, 51 (4): 342-347. 10.1097/01.mat.0000169119.06419.ed.CrossRefPubMed Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M: Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J. 2005, 51 (4): 342-347. 10.1097/01.mat.0000169119.06419.ed.CrossRefPubMed
25.
go back to reference Lohr JW, Schwab SJ: Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol. 1991, 2 (5): 961-975.PubMed Lohr JW, Schwab SJ: Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol. 1991, 2 (5): 961-975.PubMed
Metadata
Title
Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study
Authors
Karlien François
Karl Martin Wissing
Rita Jacobs
Dries Boone
Kristine Jacobs
Christian Tielemans
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-104

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.